Next-Generation Gene Editing:
Base Editor and Prime Editor

Introducing the First Off-the-Shelf Base & Prime Editing Nucleases

Overview Mechanism Highlights Product List Case Studies Contact Us

Catalog Products » GenCRISPR™ Cas9 Genome Editing Products » Next-Generation Gene Editing: Base Editor and Prime Editor

Advancing Gene Editing with Precision and Safety

Base editing and prime editing represent the latest advancements in gene editing, offering researchers greater accuracy and efficiency in correcting genetic mutations without inducing double-strand breaks, which are known to cause genomic instability and unintended mutations. Unlike traditional CRISPR approaches that rely on double-strand breaks and homology-directed repair, base and prime editors introduce precise modifications with a safer profile, reducing the risk of off-target effects and unwanted genetic disruptions.

Until now, obtaining high-quality base and prime editing nucleases required extensive optimization, hindering accessibility for many researchers. GenScript has successfully launched the first off-the-shelf base and prime editing nucleases, providing a ready-to-use solution that accelerates genetic research and therapeutic development.

CRISPR Gene Editing

Mechanism of Base Editing and Prime Editing

Base editing and prime editing are innovative gene-editing technologies derived from CRISPR-Cas systems, designed to introduce precise nucleotide changes without generating double-stranded DNA breaks.

Base Editor (BE)
Prime Editor (PE)

Base editors utilize a catalytically impaired Cas9 (nCas9 or dCas9) fused with a deaminase enzyme to convert specific DNA bases without disrupting the DNA strand. This system enables the direct conversion of cytosine (C) to thymine (T) or adenine (A) to guanine (G) in a programmable manner. Base editing provides a highly efficient, low-risk approach for correcting point mutations, making it particularly valuable for therapeutic applications targeting single-nucleotide variations.

Product Highlights

First-in-Market Solution

The first commercially available, ready-to-use BE and PE nucleases, eliminating the need for extensive optimization.

Comprehensive Product Line

Besides BE, we covers nearly all PE variants, suitable for various applications.

High Purity & Quality

Manufactured with over 90% purity to ensure reliability and consistency.

Multiple Concentrations Available

Offering concentrations from 30 µg to milligram levels to accommodate the needs of different cell types.

Product List

GenScript’s base and prime editing nucleases originate from Dr. David Liu’s lab, with patents owned by the Broad Institute. We are proud to license these technologies to provide researchers with high-quality gene-editing solutions. Our products are available for research use only (RUO). For inquiries regarding downstream commercialization, please contact us for legal guidance.

All

Prime Editor

Base Editor

Prime editor

Cat. No.	Product Name	Price
RC00003	PEmax RNase deletion	$150.00
RC00004	PE2	$400.00 100 μg(10mg/ml)
RC00005	PEmax	$200.00
RC00006	PE6b	$200.00
RC00007	PE6c	$150.00
RC00008	PE6d	$150.00
RC00009	PE7	$220.00

Base Editor

Cat. No.	Product Name	Quantity	Price	Order
RC00010	ABE8e		$200.00

Testimonials

"The people at GenScript have been tremendously helpful in providing materials for our lab. We've been able to test novel CRISPR systems such as prime editing and PASSIGE in a timely manner thanks to their work. I would recommend their services for your editing needs."

Jack Castelli

Fred Hutchinson Cancer Center

"We are very pleased with the editing efficiency using base editors from GenScript, we got up to 100% KO!"

MariaMorello Miravet

Karolinska Institutet

Case Studies

Base editor (ABE8e)

Gene editing efficiency in Jurkat cells using ABE8e RNP

High A to G conversion across different doses

ABE8e protein effectively knocks out B2M protein
Prime editor

Gene editing efficiency in HEK293T cells using PE7 RNP at 50 pmol

PE7 mediated targeted 5 bp deletions at the HEK3 locus in HEK293 cells

No significant impact on cell viability